Medicare home infusion therapy suppliers: who they are and how the benefit works
Home infusion therapy is the intravenous or subcutaneous administration of drugs or biologicals to a patient at home. Delivering it takes three things at once: the drug itself (anti-infectives, inotropes, immune globulin), the equipment (usually an ambulatory infusion pump), and the supplies (tubing, catheters, dressings). It also takes nursing: infusion nurses train the patient or caregiver to self-administer, explain side effects and therapy goals, and return to assess the access site and change dressings.
The Medicare benefit behind the enrollment category
Section 5012 of the 21st Century Cures Act, enacted on December 13, 2016, amended sections 1861(s)(2) and 1861(iii) of the Social Security Act and created a separate Medicare home infusion therapy benefit, effective January 1, 2021. It pays for the professional services that go with certain drugs given intravenously or subcutaneously through a pump that is an item of durable medical equipment (DME): nursing, training and education not already paid under DME, and remote and other monitoring, furnished under a plan of care by a qualified home infusion therapy supplier in the patient's home.
That split matters commercially. The drug, pump and supplies continue to flow through the DME and Part B channels, while the visit-based professional services are billed by an organisation enrolled under the specialty HOME INFUSION THERAPY SUPPLIER. Many enrolled organisations are also infusion pharmacies, so the same company is often both the drug dispenser and the nursing provider.
What the CMS enrollment file shows and what it leaves out
CMS publishes the enrolled suppliers as the Home Infusion Therapy Providers file on data.cms.gov. Each record carries an enrollment ID, the legal business name, the practice address and phone, the specialty, and a rendering area. The rendering area is repeated once per state (and sometimes per county or ZIP) that the supplier serves, so one enrollment can occupy dozens of rows. The 2026-11-03 release has 1,724 rows for 327 enrollments under 226 legal business names.
- Legal names, not brands. National operators enroll many locations under one legal entity, and local branches often appear under truncated legal names, so parent-company roll-ups need care.
- Footprint varies widely. Some suppliers render in a single state; specialty biologics providers can list every state plus DC.
- No website or ownership fields. The file does not name parent companies, payer contracts or therapies offered.
Who the enrolled suppliers are
| Type | Typical profile |
|---|---|
| National home infusion platforms | Multiple enrollments under one legal entity, broad multi-state rendering areas |
| Independent regional infusion pharmacies | One or a few enrollments, rendering in one or two states |
| Health-system and academic programs | Hospital- or university-owned infusion services covering their referral region |
| Home health agencies and visiting nurse associations | Nursing-led organisations adding infusion visits to home health |
| Specialty biologics providers | Focused on immune globulin and other biologics, often nationwide |
How buyers use a supplier map
- Specialty drug trade relations: match IVIG, inotrope or anti-infective distribution to suppliers that render in the target states.
- Infusion pump sales: prioritise suppliers whose rendering areas cover your sales territories.
- Corporate development: identify independent single-state suppliers as tuck-in candidates for consolidators.
- Nurse staffing: find suppliers serving states where infusion nurse coverage is thin.
Medicare enrollment confirms that an organisation is set up to bill the home infusion therapy benefit; it does not by itself describe capacity, therapy mix or commercial payer networks, which should be confirmed with each supplier.